CL2015000311A1 - El compuesto trans-clomifeno en forma particulada, con un tamaño medio de particula de menos de 30 micras, y al menos 90% de las particulas tienen un tamaño de menos de 50 micras; formulacion que lo comprende, util para el tratamiento de hipogonadismo secundario o diabetes tipo 2 en un varon o para el tratamiento de la infertilidad y el cancer de mama en una mujer, entre otras enfermedades. - Google Patents

El compuesto trans-clomifeno en forma particulada, con un tamaño medio de particula de menos de 30 micras, y al menos 90% de las particulas tienen un tamaño de menos de 50 micras; formulacion que lo comprende, util para el tratamiento de hipogonadismo secundario o diabetes tipo 2 en un varon o para el tratamiento de la infertilidad y el cancer de mama en una mujer, entre otras enfermedades.

Info

Publication number
CL2015000311A1
CL2015000311A1 CL2015000311A CL2015000311A CL2015000311A1 CL 2015000311 A1 CL2015000311 A1 CL 2015000311A1 CL 2015000311 A CL2015000311 A CL 2015000311A CL 2015000311 A CL2015000311 A CL 2015000311A CL 2015000311 A1 CL2015000311 A1 CL 2015000311A1
Authority
CL
Chile
Prior art keywords
microns
treatment
less
size
clomiphene
Prior art date
Application number
CL2015000311A
Other languages
English (en)
Spanish (es)
Inventor
Joseph S Podolski
Kuang Hsu
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48014380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015000311(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of CL2015000311A1 publication Critical patent/CL2015000311A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL2015000311A 2012-08-21 2015-02-09 El compuesto trans-clomifeno en forma particulada, con un tamaño medio de particula de menos de 30 micras, y al menos 90% de las particulas tienen un tamaño de menos de 50 micras; formulacion que lo comprende, util para el tratamiento de hipogonadismo secundario o diabetes tipo 2 en un varon o para el tratamiento de la infertilidad y el cancer de mama en una mujer, entre otras enfermedades. CL2015000311A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261691722P 2012-08-21 2012-08-21

Publications (1)

Publication Number Publication Date
CL2015000311A1 true CL2015000311A1 (es) 2015-08-14

Family

ID=48014380

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015000311A CL2015000311A1 (es) 2012-08-21 2015-02-09 El compuesto trans-clomifeno en forma particulada, con un tamaño medio de particula de menos de 30 micras, y al menos 90% de las particulas tienen un tamaño de menos de 50 micras; formulacion que lo comprende, util para el tratamiento de hipogonadismo secundario o diabetes tipo 2 en un varon o para el tratamiento de la infertilidad y el cancer de mama en una mujer, entre otras enfermedades.

Country Status (22)

Country Link
US (1) US20150202167A1 (cg-RX-API-DMAC7.html)
EP (1) EP2887922A1 (cg-RX-API-DMAC7.html)
JP (2) JP2015527360A (cg-RX-API-DMAC7.html)
KR (1) KR20150041793A (cg-RX-API-DMAC7.html)
CN (1) CN104582686A (cg-RX-API-DMAC7.html)
AU (1) AU2013306393A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015002288A2 (cg-RX-API-DMAC7.html)
CA (1) CA2880388A1 (cg-RX-API-DMAC7.html)
CL (1) CL2015000311A1 (cg-RX-API-DMAC7.html)
CR (1) CR20150096A (cg-RX-API-DMAC7.html)
EA (1) EA201590421A1 (cg-RX-API-DMAC7.html)
HK (1) HK1209636A1 (cg-RX-API-DMAC7.html)
IL (1) IL236911A0 (cg-RX-API-DMAC7.html)
IN (1) IN2015DN01698A (cg-RX-API-DMAC7.html)
MX (1) MX2015001912A (cg-RX-API-DMAC7.html)
NI (1) NI201500022A (cg-RX-API-DMAC7.html)
NZ (1) NZ704679A (cg-RX-API-DMAC7.html)
PH (1) PH12015500331A1 (cg-RX-API-DMAC7.html)
SG (2) SG10201704820SA (cg-RX-API-DMAC7.html)
UA (1) UA113324C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014031177A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201501124B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
WO2014070523A1 (en) 2012-11-02 2014-05-08 Repros Therapeutics Inc. Trans-clomiphene for use in cancer therapy
EP3015453B1 (en) 2014-10-28 2016-10-12 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of Clomiphene
EP3015454A1 (en) 2014-10-28 2016-05-04 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Stable solid form of trans-Clomiphene citrate
US11737934B2 (en) 2015-10-14 2023-08-29 Qfix Systems, Llc MRI compatible patient trolley
WO2017182097A1 (en) * 2016-04-22 2017-10-26 F.I.S. - Fabbrica Italiana Sintetici S.P.A. Process for the preparation of enclomiphene citrate having needle shaped crystal habit.
CA3098552A1 (en) 2019-11-14 2021-05-14 Apotex Inc. Processes for the preparation of zuclomiphene and intermediates thereof
CA3098725A1 (en) 2019-11-14 2021-05-14 Apotex Inc. Zuclpomiphene salts and crystalline forms thereof
CA3105944A1 (en) 2020-01-22 2021-07-22 Apotex Inc. Crystalline forms of zuclomiphene citrate
EP3907213A1 (en) 2020-05-04 2021-11-10 Pcas Processes for the production of isomerically pure or enriched cis-clomiphene
US11578025B2 (en) 2020-10-19 2023-02-14 Apotex Inc. Processes for the preparation of zuclomiphene intermediates

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914563A (en) 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
IT951631B (it) 1971-03-18 1973-07-10 Richardson Merrell Spa Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi
WO2003005954A2 (en) * 2001-07-09 2003-01-23 Zonagen, Inc. Methods and materials for the treatment of testosterone deficiency in men
WO2005101000A2 (en) * 2004-03-31 2005-10-27 Trophogen, Inc. Human glycoprotein hormone superagonists and uses thereof
US20080242726A1 (en) 2004-07-14 2008-10-02 Podolski Joseph S Trans-Clomiphene for the Treatment of Benign Prostate Hypertrophy, Porstate Cancer, Hypogonadism Elevated Triglycerides and High Cholesterol
US7476405B2 (en) * 2006-02-23 2009-01-13 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
EA017385B1 (ru) 2007-10-16 2012-12-28 Репрос Терапьютикс Инк. Применение транс-кломифена для снижения концентрации глюкозы в сыворотке
TWI458478B (zh) * 2008-11-07 2014-11-01 Repros Therapeutics Inc 用於代謝症候群與第２型糖尿病的反式氯米芬

Also Published As

Publication number Publication date
NI201500022A (es) 2016-02-01
CN104582686A (zh) 2015-04-29
IL236911A0 (en) 2015-03-31
CA2880388A1 (en) 2014-02-27
IN2015DN01698A (cg-RX-API-DMAC7.html) 2015-07-03
MX2015001912A (es) 2015-06-05
PH12015500331A1 (en) 2015-04-20
ZA201501124B (en) 2016-04-28
EP2887922A1 (en) 2015-07-01
WO2014031177A1 (en) 2014-02-27
UA113324C2 (xx) 2017-01-10
SG10201704820SA (en) 2017-07-28
JP2015527360A (ja) 2015-09-17
US20150202167A1 (en) 2015-07-23
KR20150041793A (ko) 2015-04-17
SG11201500641TA (en) 2015-04-29
HK1209636A1 (en) 2016-04-08
AU2013306393A1 (en) 2015-02-19
NZ704679A (en) 2016-02-26
CR20150096A (es) 2015-05-04
JP2017206562A (ja) 2017-11-24
BR112015002288A2 (pt) 2017-07-04
EA201590421A1 (ru) 2015-06-30

Similar Documents

Publication Publication Date Title
CL2015000311A1 (es) El compuesto trans-clomifeno en forma particulada, con un tamaño medio de particula de menos de 30 micras, y al menos 90% de las particulas tienen un tamaño de menos de 50 micras; formulacion que lo comprende, util para el tratamiento de hipogonadismo secundario o diabetes tipo 2 en un varon o para el tratamiento de la infertilidad y el cancer de mama en una mujer, entre otras enfermedades.
RU2016118771A3 (en) Co-crystals and pharmaceutical compositions comprising the same
GB201302427D0 (en) Nanoparticle delivery compositions
IT1401882B1 (it) Nanoparticelle autoassemblanti per il rilascio di bifosfonati nel trattamento di tumori.
IL246654A0 (en) A pyridylamino acetic acid compound and a medical preparation containing polyoxyethylene castor oil
IL241823B (en) Preparations containing novyi .c and their uses for the treatment of cancerous tumors
JP2013145868A5 (cg-RX-API-DMAC7.html)
SMT201800528T1 (it) Composizione a base di flavonoidi per uso farmaceutico, nutrizionale o cosmetico con potenziata azione antiossidante
WO2017079403A3 (en) Polymeric nanoparticles
HUE067358T2 (hu) Szilárd ásványi anyagokon alapuló összetételek és az azokat tartalmazó orálisan dezintegráló készítmények
JP2013236836A5 (cg-RX-API-DMAC7.html)
IT1401289B1 (it) Composti dotati di attivita' antiossidante nei confronti dei radicali liberi, e composizioni farmaceutiche e cosmetiche che li contengono
PT2895192T (pt) Uma composição farmacêutica compreendendo uma nanopartícula sólida e pelo menos um antígeno para o tratamento contra um agente patogénico intracelular
WO2015112168A3 (en) Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
JP2014089347A5 (cg-RX-API-DMAC7.html)
AR105413A1 (es) Composición farmacéutica para el tratamiento de enfermedades gastrointestinales
GB2527878B (en) Theoretical collision cross section ("CCS") in experimental design
PT3233126T (pt) Nanopartículas para encapsular compostos, sua preparação e utilizações
SI2953617T1 (sl) Farmacevtski sestavki, ki vključujejo nizkoodmerna zdravila
JP2014011706A5 (cg-RX-API-DMAC7.html)
JP2014011707A5 (cg-RX-API-DMAC7.html)
VOMACKA Le journal de l'écuyer Jaroslav
ZA201901907B (en) Solid composition for quick ingestion with facilitated swallowing, in the form of solid, non-agglomerated particles, comprising two different types of particles
CN302029911S (zh) 前门内护板
CN302229107S (zh) 压蒜器